Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just added.
https://www.youtube.com/watch?v=ReBx1FL1s24
https://www.openaccessgovernment.org/dpyd-genotyping/114349/
https://www.openaccessgovernment.org/clinic/114309/
COVID-19 Testing at Leeds Bradford Airport
https://twitter.com/nph_group/status/1407693894502977543
A video showing the #COVID19 sample PCR testing process
https://twitter.com/Yourgene_Health/status/1407632032843419648
DPYD testing kits
https://bidstats.uk/tenders/2021/W24/752943389
Earlier this year, Yourgene Health entered into a collaboration with Cytox to run their genoSCORE-LAB assay in our laboratory. genoSCORE-LAB™ is a new non-invasive test that can predict the risk of an individual developing Alzheimer’s disease from a simple saliva sample
https://www.openaccessgovernment.org/precision-medicine-in-action-alzheimers-disease-polygenic-risk-scores/113112/
This is just a Reminder.
7 notices over 12 months.
6 unique titles
100% are awards
100% have published value
£15B highest value contract
£2B median contract value
https://bidstats.uk/analysis/contracts?q=yourgene+health
Multi-year licence and supply agreement with leading US precision medicine company
Manchester, UK – 9 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has entered into a licence and supply agreement (the “Agreement”) with a leading US precision medicine company (the “Partner”) for an initial term of three years commencing 1 April 2022. The Agreement grants the Partner a non-exclusive licence to the Company’s FlexTM Analysis Software and commits Yourgene to supplying sample preparation reagents and instrumentation to support the planned launch of a new clinical reproductive health screening service across all US states by the Partner. The Agreement allows for automatic annual renewals after the initial term, subject to typical notice provisions.
The Partner is a leading precision medicine organisation with an established franchise in genetic diagnostics, who wishes to build a significant market presence in the rapidly growing US reproductive health diagnostics sector. After a competitive process the Partner has chosen to partner with Yourgene, given its unique sample preparation technology, bioinformatics expertise and flexible approach to customising its workflow.
The three-year initial contract term enables the Partner to launch a reproductive health screening test in the Company’s financial year 2022-23. The screening test will connect the Partner’s sample processing workflow with the Company’s proprietary bioinformatics FlexTM Analysis Software as well as its Ranger® Technology - the sample enrichment technology acquired through Coastal Genomics in August 2020. The planned launch of the testing service will follow an in-depth customised workflow development and a validation and verification phase prior to launch. The latter process is designed to support attainment of laboratory accreditations for the Partner’s laboratory, enabling them to offer the reproductive health screening test.
Yourgene Flex™ is the Company’s modular next-generation sequencing (NGS) analysis framework which harnesses best-in-class bioinformatics pipelines to offer high quality, robust yet flexible NGS analysis solutions. Flex™ is enabling Yourgene to support its diagnostic product development partnerships and research collaborations with key industry players, as well as being deployed to support Yourgene’s internal product development pipeline across reproductive health and oncology.
Lyn Rees, Chief Executive Officer of Yourgene Health, commented: “We are extremely pleased to sign this agreement with such a prestigious US company and this is a strong endorsement of our software and technology expertise. This collaboration aligns with our strategic goal of providing partners with the best-in-class instrumentation and medical software analysis capabilities. We look forward to enabling our partner to launch a competitive clinical offering into the US market in 2022 and we anticipate that this partnership will g
https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/8127-Medical-Single.pdf
In late 2018, we launched a strategic planning process which has delivered an ambitious plan to create a significant molecular genetics business and deliver material increases in shareholder value in the next 3-5 years. We aim to achieve this through a combination of greater penetration of our existing markets with our current products, geographic expansion, bringing new products to market, scalable business processes, a dynamic performance-oriented culture and inorganic growth through acquisition and/or licensing. This business plan is being embedded and cascaded throughout the Group to ensure that execution of the strategy and our customers are at the forefront of everything we do.
https://www.investegate.co.uk/yourgene-health-plc/rns/final-results--business-update-and-director-change/201907100700029954E/
NIPT to be evaluated as a new part of NHS screening pathway for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome
https://phescreening.blog.gov.uk/tag/nipt/
We are pleased to inform patients that from 1st June 2021, non-invasive prenatal testing (NIPT) will be offered within the national screening pathway for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome.
https://www.stgeorges.nhs.uk/service/maternity-services/your-pregnancy/fetal-medicine-unit/the-safe-test/
Non-invasive prenatal testing (NIPT) is currently being rolled out across England.
https://www.gov.uk/government/publications/downs-syndrome-edwards-syndrome-and-pataus-syndrome-options-after-a-higher-chance-screening-result/your-choices-after-a-higher-chance-screening-result
https://www.agbl.net/our-partners/ Yourgene is already here!
Manchester, UK - 19 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it is launching a Distribution Partnership with Dubai-headquartered Alliance Global FZ LLC ('AGBL' or 'Alliance Global') across a broad range of territories in the Middle East and Africa to expand the Company's geographical footprint and its customer base.
Alliance Global is the largest biomedical gateway in the Middle East, Africa, and Asia and is both a well-respected and a long-term partner for many international and U.S. diagnostics groups looking to pursue a strategy of expansion in these regions. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the regions' emerging healthcare market. AGBL is a well-positioned platform agnostic partner for Yourgene, working with key providers of both PCR and sequencing technologies. AGBL will be focusing on Yourgene's product portfolio of non-invasive prenatal testing ('NIPT'), the reproductive health range including Cystic Fibrosis and QST*R rapid aneuploidy analysis, DPYD genotyping and the new size selection and enrichment technologies, Yourgene QS250 and LightBench™.
In response to the restriction on travel to key regions as a result of the COVID-19 pandemic, Yourgene has reviewed it's strategy for bringing products to market in new territories. Following a review of the Company's channels across its international markets, the commitment and focus with a local network in the Middle East and Africa provided by AGBL, is expected to generate future growth opportunities for the Company. AGBL has strong technical expertise to distribute and support Yourgene's growing product range and customer base across these regions, offering an expansive geographic reach and more commercial drivers on the ground to meet the needs of this exciting, emerging international market.
Commenting, Lyn Rees, CEO of Yourgene, said: "This partnership with AGBL is a really exciting progression for Yourgene and our product portfolio as we continue to expand into further territories. AGBL will provide a strong and well positioned channel to allow us to deliver and drive growth for our current and future products. This is a key international market for Yourgene and we look forward to working with AGBL and utilising their expertise to secure further market penetration and geographic expansion."
Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partner MyHealthChecked plc (AIM:MHC) ("MyHealthChecked") has signed a second COVID-19 testing services agreement, to support the supply of the MyHealthChecked™ COVID-19 at-home nasal swab kit, PCR laboratory testing service and logistics for day two and day eight ("D2/D8") coronavirus testing for international arrivals, to Boots UK Limited ("Boots"), the health and beauty retailer and pharmacy group.
Through the service agreement, a proportion of the MyHealthChecked™ COVID-19 tests will be processed by Yourgene Genomic Services ("YGS") at the Company's Citylabs 1.0 laboratory in Manchester which are well equipped to deal with the anticipated increased demand for D2/D8 testing. In addition, samples processed at MyHealthChecked's own laboratories will use Yourgene's Clarigene® SARS CoV-2 PCR CE-IVD test kit. MyHealthChecked is currently the only at-home testing kit provider within Boots for General Testing and Fit-to-Fly services, as launched on 7 April 2021, and is now accompanied by D2/D8 tests that will be available to purchase online, via www.boots.com across the UK, from 17 May 2021.
Lyn Rees, CEO of Yourgene Health and Non-Executive Director of MyHealthChecked, commented: "This further contract with Boots is another significant milestone for MyHealthChecked and Yourgene is pleased to continue supporting their COVID-19 testing service and product supply to their laboratory. With the introduction of the new traffic light system in the UK for global travel, we will see an increased demand for D2/D8 testing, as travel resumes, and this further contract for MyHealthChecked is a testament to the quality of the service provided."
To meet the minimum standard required by the government, companies must provide:
both Covid-19 test kits
delivery and (where relevant) test swabbing
full evaluation of the test samples
relevant genome sequencing activities
result reporting to the patient
data reporting to PHE
https://www.thenorthernecho.co.uk/news/19294462.companies-post-travel-covid-tests-north-east-yorkshire/